HAYWARD, Calif.– Aarvik Therapeutics, a biotechnology company focused on antibody drug conjugates (ADCs) for cancer treatment, announced it has successfully closed a Series Seed 2 financing round. The funding drew participation from original Series Seed investors as well as a new group that includes pharma and technology professionals, and contract research and manufacturing organizations.
Founded in 2021, Aarvik launched with an initial Series Seed round and established laboratories in Hayward, where it developed its proprietary MUTTA™ (MUlti-epitope Targeting Tetravalent Antibody) platform. The approach is designed to broaden the impact of ADC therapies beyond a small set of targets by lowering the minimum effective dose while maintaining or improving the maximum tolerated dose, thereby significantly expanding the therapeutic window. In August 2024, the company exercised an option to exclusively license its research collaboration program, further strengthening its pipeline.
The new funding will support Aarvik in reaching targeted research milestones and advancing its portfolio of ADC assets.
“We are delighted to see Aarvik reach this new milestone,” said Ram K. Reddy, serial entrepreneur, venture partner and independent board member of Aarvik Therapeutics. “The support from new as well as existing investors is a reflection of the progress achieved by Aarvik and the potential of its pipeline.”
“Aarvik continues to demonstrate that it can combine its deep ADC drug development expertise with its next-generation MUTTA™ platform to enable powerful oncology therapies,” added Jagath Reddy Junutula, Ph.D., co-founder, president and CEO of Aarvik Therapeutics. “Aarvik relentlessly pursues novel therapies for hard-to-treat cancer indications through research and innovation.”
